Global and United States Recombinant Human EGF Market Report & Forecast 2022-2028

Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.
This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.
Market Analysis and Insights: Global and United States Recombinant Human EGF Market
This report focuses on global and United States Recombinant Human EGF market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Recombinant Human EGF market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, ≥98% SDS-PAGE accounting for % of the Recombinant Human EGF global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Scientific Research was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.
This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.
The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell – a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR – that ultimately lead to DNA synthesis and cell proliferation.
Global Recombinant Human EGF Scope and Market Size
Recombinant Human EGF market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Human EGF market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Recombinant Human EGF market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
≥98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Segment by Application
Scientific Research
Medical Drug
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience